GALT icon

Galectin Therapeutics
GALT

Overview Fund Trends Analyst Outlook Journalist POV

59 hedge funds and large institutions have $18.2M invested in Galectin Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

more call options, than puts

Call options by funds: $ | Put options by funds: $

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more capital invested

Capital invested by funds: $ → $

more ownership

Funds ownership: →

11% less funds holding

Funds holding: 66 → 59 (-7)

64% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 11

Holders
59
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$154K
Puts
$16K
Net Calls
Net Calls Change

Top Buyers

1
+$671K
2
+$513K
3
+$126K
4
Squarepoint
Squarepoint
New York
+$115K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$90.9K

Top Sellers

1
-$444K
2
-$184K
3
-$90K
4
AWS
Atria Wealth Solutions
New York
-$83.7K
5
IAA
Independent Advisor Alliance
North Carolina
-$59.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
51
$9.16K
52
$9.12K
53
$7.12K
54
$4.47K
55
$4K
56
$2.39K
57
$1.29K
58
$598
59
$400
60
–
61
–
62
–
63
–
64
–
65
–
66
–
67
–
68
–
69
–
70
–
1 2
3